You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The reimbursement rates for the most commonly performed SARS-CoV-2 serologic tests are $42.13 and $45.23, depending on the billing code used.
The Abbott test had fewer false positive and false negative results but diagnostic sensitivity in both tests was poor during the first two weeks of symptoms, the study said.
A recent study from New York University found Abbott's ID Now rapid point-of-care test could return false negative results.
The paper, which is not peer-reviewed, said that use of the test as a first-step screening tool would require confirmation of more than 80 percent of its results.
The PCR-based test received EUA for use on the Alinity m platform after receiving authorization in March on the firm's m2000 RealTime System.
Only 2.5 percent of Americans have been tested for COVID-19, even as industry scrambles to increase testing capacity and a second wave of cases may hit in the fall.
The company said it expects to ship nearly 30 million of its SARS-CoV-2 serology tests in May globally and will have capacity for 60 million tests in June.
Siemens Healthineers got the nod for its Advia Centaur CA 125 II Assay for detecting CA 125 to help in the management of patients with ovarian carcinoma.
The test detects IgG antibodies in human serum and plasma and is intended to identify people with an adaptive immune response to SARS-CoV-2.
Abbott's RealTime CT/NG assay is currently only cleared by the US Food and Drug Administration for use with urogenital samples.